ArticleJournal of immunology (Baltimore, Md. : 1950)2009
Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 89 citations in OpenAlex.
- Chemerin 15 enhances microglial phagocytosis to attenuate cerebral ischemia-reperfusion injury through the ChemR23/p38 MAPK pathway.iScience · 2025Article
- Chemerin-9 is neuroprotective in APP/PS1 transgenic mice by inhibiting NLRP3 inflammasome and promoting microglial clearance of Aβ.Journal of neuroinflammation · 2025Article
- A Cross-Sectional Study: Systematic Quantification of Chemerin in Human Cerebrospinal Fluid.Biomedicines · 2024Article
- Chemerin triggers migration of a CD8 T cell subset with natural killer cell functions.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- The Role of Adipokines in the Pathologies of the Central Nervous System.International journal of molecular sciences · 2023Review
- Up-regulation of CMKLR1 in endometriosis and its relationship with inflammatory responses.Histology and histopathology · 2023Article
- Chemerin and Chemokine-like Receptor 1 Expression Are Associated with Hepatocellular Carcinoma Progression in European Patients.Biomedicines · 2023Article
- Amniotic fluid biomarkers predict the severity of congenital cytomegalovirus infection.The Journal of clinical investigation · 2022Article
- Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction.Journal of translational medicine · 2022Review
- Circulating Chemerin and Its Kinetics May Be a Useful Diagnostic and Prognostic Biomarker in Critically Ill Patients with Sepsis: A Prospective Study.Biomolecules · 2022Article
- Multiple sclerosis and obesity: The role of adipokines.Frontiers in immunology · 2022Review
- Adipokines as Immune Cell Modulators in Multiple Sclerosis.International journal of molecular sciences · 2021Review
- The antitumoral effects of chemerin are independent from leukocyte recruitment and mediated by inhibition of neoangiogenesis.Oncotarget · 2021Article
- The complex role of adipokines in obesity, inflammation, and autoimmunity.Clinical science (London, England : 1979) · 2021Review
- n-3 Polyunsaturated Fatty Acids and Their Derivates Reduce Neuroinflammation during Aging.Nutrients · 2020Review
- Chemerin-induced macrophages pyroptosis in fetal brain tissue leads to cognitive disorder in offspring of diabetic dams.Journal of neuroinflammation · 2019Article
- Novel CMKLR1 Inhibitors for Application in Demyelinating Disease.Scientific reports · 2019Article
- DGAT1 inhibits retinol-dependent regulatory T cell formation and mediates autoimmune encephalomyelitis.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis.Frontiers in oncology · 2019Article
- N-3 Polyunsaturated Fatty Acids and the Resolution of Neuroinflammation.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We examined the involvement of chemokine-like receptor-1 (CMKLR1) in experimental autoimmune encephalomyelitis (EAE), a model of human multiple sclerosis. Upon EAE induction by active immunization with myelin oligodendrocyte glycoprotein amino acids 35-55 (MOG(35-55)), microglial cells and CNS-infiltrating myeloid dendritic cells expressed CMKLR1, as determined by flow cytometric analysis. In addition, chemerin, a natural ligand for CMKLR1, was up-regulated in the CNS of mice with EAE. We found that CMKLR1-deficient (CMKLR1 knockout (KO)) mice develop less severe clinical and histologic disease than their wild-type (WT) counterparts. CMKLR1 KO lymphocytes proliferate and produce proinflammatory cytokines in vitro, yet MOG(35-55)-reactive CMKLR1 KO lymphocytes are deficient in their ability to induce EAE by adoptive transfer to WT or CMKLR1 KO recipients. Moreover, CMKLR1 KO recipients fail to fully support EAE induction by transferred MOG-reactive WT lymphocytes. The results imply involvement of CMKLR1 in both the induction and effector phases of disease. We conclude that CMKLR1 participates in the inflammatory mechanisms of EAE and represents a potential therapeutic target in multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.